Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of ZN-c5 Alone and in Combination With Palbociclib in Subjects With Estrogen-Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer

NCT03560531 is registered in ClinicalTrials.gov with Zeno Alpha Inc. as lead sponsor.

NCT NCT03560531
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03560531 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of ZN-c5 Alone and in Combination With Palbociclib in Subjects With Estrogen-Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer
Lead sponsor
Zeno Alpha Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
November 30, 2018
Completion date
December 22, 2022
Enrollment
181 (actual)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer